InvestorsHub Logo

H2R

Followers 42
Posts 2176
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: None

Friday, 06/17/2022 7:42:39 AM

Friday, June 17, 2022 7:42:39 AM

Post# of 1569
PDUFA now Feb. 28, 2023

(Nasdaq: CYTK) today announced that, in response to a request from the U.S. Food and Drug Administration (FDA), the company recently provided additional pharmacokinetic analyses of omecamtiv mecarbil related to the company’s new drug application (NDA). After an initial review of the company’s submission, FDA has communicated that the additional data provided constitutes a major amendment to the NDA and has extended the PDUFA date by three months to February 28, 2023 to provide time for a full review of the submission.



Best of luck with your investments!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTK News